Novartis Trial Failure Sparks Biopharma Options Frenzy

A high-profile Novartis clinical-trial failure triggered unusually heavy options activity across biopharma stocks, signaling heightened sector volatility and investor concern. The failure has sent shockwaves through the group, with derivatives markets reflecting increased positioning around biotech risk.